News Releases Keyword Search Year None202220212020201920182017201620152014 Nov 21, 2022 Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference Nov 03, 2022 Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress Nov 03, 2022 Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses Oct 12, 2022 Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) Oct 10, 2022 Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa Oct 03, 2022 Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock Oct 03, 2022 Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock Sep 30, 2022 Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 Sep 27, 2022 Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference Sep 20, 2022 Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy Sep 16, 2022 Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 Sep 06, 2022 Rocket Pharmaceuticals to Present at Morgan Stanley 20th Annual Global Healthcare Conference Aug 08, 2022 Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress Jul 27, 2022 Rocket Pharmaceuticals Appoints Mayo Pujols as Chief Technical Officer and Strengthens Manufacturing Capabilities Jul 08, 2022 Rocket Pharmaceuticals to Present at William Blair Biotech Focus Conference May 19, 2022 Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) May 16, 2022 Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) May 11, 2022 Rocket Pharmaceuticals to Present at UBS Global Healthcare Conference May 05, 2022 Rocket Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Progress Apr 27, 2022 Rocket Pharmaceuticals to Present at the Bank of America Securities 2022 Global Healthcare Conference Mar 29, 2022 Rocket Pharmaceuticals to Present at Upcoming Investor Conferences Mar 14, 2022 Rocket Pharmaceuticals Appoints Fady Malik, M.D., Ph.D., to Board of Directors Mar 08, 2022 Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance Feb 24, 2022 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial and Operational Results Feb 10, 2022 Rocket Pharmaceuticals Announces Participation in 11th Annual SVB Leerink Global Healthcare Conference Jan 11, 2022 Rocket Pharmaceuticals Highlights Anticipated 2022 Milestones Across Lentiviral and AAV Gene Therapy Clinical Programs Jan 04, 2022 Rocket Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference Print Page RSS E-mail Alerts Contact
Keyword Search Year None202220212020201920182017201620152014 Nov 21, 2022 Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference Nov 03, 2022 Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress Nov 03, 2022 Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses Oct 12, 2022 Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) Oct 10, 2022 Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa Oct 03, 2022 Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock Oct 03, 2022 Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock Sep 30, 2022 Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 Sep 27, 2022 Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference Sep 20, 2022 Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy Sep 16, 2022 Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 Sep 06, 2022 Rocket Pharmaceuticals to Present at Morgan Stanley 20th Annual Global Healthcare Conference Aug 08, 2022 Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress Jul 27, 2022 Rocket Pharmaceuticals Appoints Mayo Pujols as Chief Technical Officer and Strengthens Manufacturing Capabilities Jul 08, 2022 Rocket Pharmaceuticals to Present at William Blair Biotech Focus Conference May 19, 2022 Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) May 16, 2022 Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) May 11, 2022 Rocket Pharmaceuticals to Present at UBS Global Healthcare Conference May 05, 2022 Rocket Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Progress Apr 27, 2022 Rocket Pharmaceuticals to Present at the Bank of America Securities 2022 Global Healthcare Conference Mar 29, 2022 Rocket Pharmaceuticals to Present at Upcoming Investor Conferences Mar 14, 2022 Rocket Pharmaceuticals Appoints Fady Malik, M.D., Ph.D., to Board of Directors Mar 08, 2022 Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance Feb 24, 2022 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial and Operational Results Feb 10, 2022 Rocket Pharmaceuticals Announces Participation in 11th Annual SVB Leerink Global Healthcare Conference Jan 11, 2022 Rocket Pharmaceuticals Highlights Anticipated 2022 Milestones Across Lentiviral and AAV Gene Therapy Clinical Programs Jan 04, 2022 Rocket Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
Nov 03, 2022 Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
Nov 03, 2022 Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses
Oct 12, 2022 Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
Sep 30, 2022 Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
Sep 20, 2022 Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy
Sep 16, 2022 Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
Sep 06, 2022 Rocket Pharmaceuticals to Present at Morgan Stanley 20th Annual Global Healthcare Conference
Aug 08, 2022 Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
Jul 27, 2022 Rocket Pharmaceuticals Appoints Mayo Pujols as Chief Technical Officer and Strengthens Manufacturing Capabilities
May 19, 2022 Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
May 16, 2022 Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
May 05, 2022 Rocket Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Progress
Apr 27, 2022 Rocket Pharmaceuticals to Present at the Bank of America Securities 2022 Global Healthcare Conference
Mar 08, 2022 Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance
Feb 24, 2022 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial and Operational Results
Feb 10, 2022 Rocket Pharmaceuticals Announces Participation in 11th Annual SVB Leerink Global Healthcare Conference
Jan 11, 2022 Rocket Pharmaceuticals Highlights Anticipated 2022 Milestones Across Lentiviral and AAV Gene Therapy Clinical Programs
